1. New Zealand Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Pacific Edge Limited

Pacific Edge Limited

0.19
AUD
+0.01
(+2.70%)
-0.03EPS
148.28MMarket Cap
Nov 19Next Earn
Pacific Edge Limited
ASX:PEB
(Australian Securities Exchange)

Recent

price

0.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
NZD
- -
- -
- -
- -
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
0.02
0.03
0.03
0.01
Revenue per Share
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.05
-0.04
-0.03
-0.03
-0.02
-0.03
-0.03
-0.04
-0.04
-0.04
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.06
0.03
0.06
0.03
0.07
0.05
0.03
0.03
0.02
0.03
0.13
0.1
0.07
0.03
0.01
Book Value per Share
0.01
0.06
0.03
0.06
0.03
0.07
0.05
0.03
0.03
0.02
0.03
0.13
0.1
0.07
0.03
0.01
Tangible Book Value per Share
208
262
320
337
345
387
410
466
514
581
714
768
810
811
812
945
Basic Weighted Avg Shares
- -
- -
- -
- -
2
5
8
3
4
4
8
11
20
24
22
11
Sales/Revenue/Turnover
-584,798.4
-48,059.53
-48,743.9
-6,937.73
-682.28
-359.64
-278.5
-630.74
-506.65
-453.91
-219.74
-193.85
-170.58
-153.85
-156.11
-339.71
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
- -
1
- -
- -
1
3
2
2
Depreciation Expense
-3
-4
-7
-10
-11
-16
-21
-20
-18
-19
-14
-20
-27
-30
-30
-36
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-624,600
-42,412.9
-46,045.8
-6,853.54
-564.78
-315.07
-260.24
-577.76
-469.43
-432.17
-184.69
-172.9
-137.46
-123.54
-137.03
-311.14
Profit Margin (%)
4
17
10
20
10
29
20
26
21
26
42
106
78
50
21
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
1
- -
3
1
- -
LT Debt
3
18
11
22
12
30
21
17
14
15
25
108
83
55
26
11
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-162.53
-39.98
-47.98
-59.47
-62.71
-75.18
-82.87
-104.85
-117.3
-132.93
-71.81
-29.65
-28.22
-43
-74.18
-194.74
Return on Common Equity (%)

Capital Structure

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

NZD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

NZD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.34%
32.52%
-59.14%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
10.52%
21.16%
19.51%
Sales/Revenue/Turnover
19.31%
17.18%
-47.36%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
24
2025
- -
- -
22
2026
- -
- -
11

Semi-annual Earnings Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.04
2026
- -
- -
-0.04

Semi-annual Dividends Per Share

NZD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Pacific Edge Limited (NZX: PEB), founded in 2001 and headquartered in Dunedin, New Zealand, specializes in the discovery, development, and commercialization of molecular diagnostic and prognostic tests for the early detection and management of bladder cancer; the company operates central laboratories in New Zealand and the United States, serving urologists and healthcare providers globally with non-invasive urine-based assays that utilize genetic and phenotypic biomarkers for superior accuracy over traditional cytology. Its core commercial portfolio comprises the Cxbladder suite of four proprietary tests—Cxbladder Detect, Triage, Monitor, and a suite addressing hematuria investigation, initial triage, post-treatment surveillance, and recurrence monitoring—validated through international multi-center clinical studies and included in the American Urological Association (AUA) guidelines for microhematuria evaluation; these products target unmet needs in urothelial cancer pathways, enabling faster clinical decisions, reduced cystoscopies, and improved patient outcomes in markets including North America, Europe, and Asia-Pacific. Pacific Edge segments its operations into Commercial (laboratory testing and sales worldwide) and Research (ongoing R&D in New Zealand and Australia), with approximately 114 employees supporting product innovation, regulatory compliance, and market access efforts. In recent developments, Pacific Edge launched a NZ$20 million capital raise in May 2025, comprising a NZ$15 million placement to institutional investors and a NZ$5 million share purchase plan for retail shareholders at NZ$0.10 per share, successfully securing NZ$16 million in the placement with oversubscriptions and closing the SPP with NZ$20.7 million total pledges by July 2025 to extend cash reserves beyond 12 months amid U.S. Medicare non-coverage for certain tests effective April 2025; proceeds fund accelerated Cxbladder Triage adoption leveraging AUA guideline inclusion, clinical evidence generation for enhanced Triage Plus and Monitor Plus variants, appeals for Medicare reconsideration, growth in non-Medicare U.S. channels, and development of in-vitro diagnostic (IVD) kits for decentralized international deployment. The company continues advancing its first-mover advantage in bladder cancer diagnostics, with directors and senior management participating in the equity raise and robust FY25 financials underscoring commercial momentum despite reimbursement challenges.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Pacific Edge Limited (PFGTF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Pacific Edge Limited (PFGTF) Q4 2026 Earnings Call Transcript